The B apolipoproteins, apo-B48 and apo-B100, are key proteins in mammalian lipoprotein metabolism and are components of all classes of lipoproteins considered to be atherogenic. Our laboratory has generated an array of genetically modified mice for studying apo-B biology. Using gene targeting in mouse embryonic stem cells, we have generated apo-Bdeficient mice. Heterozygotes had low plasma levels of apo-B and cholesterol ; homozygotes died early in embryonic development, most likely because the absence of lipoprotein secretion by the yolk sac interfered with the delivery of lipid nutrients to the developing embryo.
apo-B-containing lipoproteins, most of the reduction in the plasma cholesterol levels could be accounted for by decreased levels of high density lipoproteins (HDL). Huang and co-workers (10) have independently generated apo-B knockout mice and have analyzed the metabolic basis for the low HDL cholesterol levels ; they concluded that the reduced HDL cholesterol levels in apo-B+/-mice are due to decreased HDL cholesterol ester and apo-Al transport rates. One of the most striking features of the apo-B+/-mice was that they were protected from the development of hypercholesterolemia in response to a high-fat, high-cholesterol diet (9). On that diet, the apo-B+/-mice had significantly reduced total cholesterol levels because of reduced plasma levels of very low density lipoproteins (VLDL) and low density lipoproteins (LDL). We suspect that the lower levels of cholesterol in the apo-B+/-mice were largely due to diminished lipoprotein synthesis by the liver rather than to impaired intestinal function. Using a dual-isotope method (11, 12), we measured intestinal cholesterol absorption in six apo-B+/-mice and six wild-type mice. Both groups were fed a high-fat diet. The percentage of cholesterol that was absorbed in the apo-B+/-mice (31%) was no different from the percent absorbed in the wild-type mice (36%).
In a pilot experiment, we investigated whether the decreased susceptibility to diet-induced hypercholeste-
Insertion Vector
Apo-B Allele Targeted Apo-B Allele Fig. 1 . Sequence-insertion gene-targeting strategy for inactivating the apolipoprotein (apo-) B gene in mice. To generate the sequence-insertion vector (LF5A), we initially cloned a neo into the polylinker Hindlll site of pBSSKII. A 6-kb Sac" fragment containing the 5' portion of the mouse apo-B gene was then cloned into the polylinker Sad site. The vector was linearized at a unique Sfil site within the segment of homology and electroporated into embryonic stem (ES) cells.
The insertion of this vector into the cognate gene is predicted to interrupt the coding sequence after exon 4 and result in the synthesis of a truncated apo-B protein containing less than 2% of the full-length apo-B100.
The insertion of this vector into the apo-B locus results in a downstream duplication of a portion of exon 1 and exons 2 to 4 ; however, all mRNA-splicing events from exon 4 to the downstream exons supplied by the vector result in frameshifts.
Drug-resistant ES cell clones were screened by Southern blot analysis with an external probe located 5' to the sequences in the targeting vector. Targeted clones were identified by the presence of a novel 12.9-kb EcoRl restriction fragment. Targeted ES cells were utilized to generate chimeric mice, which were then bred to generate apo-B-deficient mice. E, EcoRI ; S, Sad F, Sfil. Reproduced, with permission, from Farese et al. (9) . rolemia in the apo-B+/-mice was accompanied by a reduction in aortic atherosclerosis.
Six apo-B+/-mice and six wild-type littermate controls (C57BL/6 x 129) were fed a high-fat diet for 1 year. The apo-B+/-mice had lower levels of total cholesterol, largely because of reduced levels of VLDL cholesterol (Fig. 2) . Fatty streak lesions in the proximal aorta were analyzed in 10 progressive sections of the ascending aorta (13). The mean lesion size per section was smaller in the apo-B+/-mice than in the wild-type control mice (3151 vs. 11,661 g M2), although this difference did not achieve statistical significance.
The apo-B+/-mice were intercrossed to produce homozygous apo-B knockout mice (apo-B-/-).
Most of the apo-B-/-mice died early during embryonic development (approximately embryonic day 10 to 12) (9). The few apo-B-/-embryos that survived until later in gestation appeared pale and had severe abnormalities in the central nervous system and cranium. This phenotype was similar to but more severe than that previously observed in gene-targeted mice that produced a truncated form of apo-B, apo-B70 (14). Recently, Farese and co-workers (15) studied the pathologic basis for the developmental abnormality in the apo-B-/-mice. They found that the visceral endoderm of the yolk sac of the apo-B-/-mice was devoid of lipoprotein production and contained an abnormal accumulation of cytosolic fat droplets. The apo-B-/-embryos had reduced stores of cholesterol and virtually absent levels of a -tocopherol. They suggested that the developmental abnormalities in the apo-B-/-mice could be due to reduced lipoprotein formation by the yolk sac, which could result in impaired delivery of lipid nutrients to the developing embryo.
Transgenic Mice Expressing Human Apo-B Within a few years after the apo-B gene was cloned, Blackhart and co-workers (16) used a combination of apo-B cDNA and genomic clones to construct an apo-B minigene expression vector. Although the apo-B minigenes yielded human apo-B expression in transfected cells, the vectors did not work well in transgenic mice. Only one human apo-B transgenic mouse was ever produced, and that mouse expressed negligible amounts of human apo-B (17). Generating "high-expressing" transgenic mice depended upon abandoning the minigene approach and using large genomic DNA fragments spanning the entire human apo-B gene.
In our early studies, we generated transgenic mice with an 80-kb fragment of genomic DNA from a P1 bacteriophage clone, p158 (Fig. 3) . In addition to the structural gene, p158 contained 19-kb of 5' flanking sequences and 17.5-kb of 3' flanking sequences.
For several of the transgenic lines, the plasma levels of human apo-B100 in transgenic mice Fig. 2 . Distribution of cholesterol in the plasma of apo-B+/-mice and wild-type control mice on a high-fat diet. A total of 200 iil of plasma (pooled from six mice of each type) was fractionated on a Superose 6 10/50 column (9,13). The cholesterol in each fraction was measured enzymatically (9,13).
consuming a low-fat chow diet were 60 to 80 mg/dl, approximately the same as those found in normolipidemic human subjects.
The human apo-B transgenic animals had increased plasma levels of cholesterol and triglycerides ; these increased lipid levels were due to a substantial increase in the mass of LDL.
When fed a high-fat diet, both the nontransgenic and the human apo-B transgenic mice developed increased VLDL cholesterol levels ; however, the LDL cholesterol levels remained strikingly and disproportionately elevated in the transgenic mice (13). As a result of the increased Section 1 is in the proximal aortic sinus where the aortic valve leaflets first appear.
At 18 weeks, the transgenic animals had fatty streak lesions, but after 24 weeks, more advanced lesions with dense fibrous caps were noted. Modified, with permission, from Purcell-Huynh et al. (13). not affect the plasma levels of mouse apo-B (13). In preliminary studies, we have assessed mouse apo-B secretion in primary hepatocytes from transgenic and nontransgenic animals. Total apo-B production was increased two-to threefold in the transgenic hepato cytes ; however, the synthesis and secretion of mouse apo-B appeared to be identical in the transgenic and nontransgenic hepatocytes (unpublished observations, M. Veniant, J Boren, and S. Young).
Several aspects of the phenotype of the human apo-B transgenic mice remain enigmatic.
First, the composition of the transgenic mouse LDL is markedly different from LDL isolated from the plasma of humans.
The LDL from human plasma contains very low levels of triglycerides, whereas the LDL from transgenic mice is enriched in triglycerides.
Recently, Fan and co-workers (18) used p158 to generate human apo-B transgenic rabbits and documented that the plasma of the transgenic rabbits also contains triglyceride-enriched LDL. Although we do not yet understand the metabolic basis for the triglyceride enrichment of LDL, it seems quite possible that this finding will emerge as a metabolic hallmark of apo-B overexpression.
We have speculated that overexpression of apo-B might lead to the production of smaller lipoproteins containing reduced amounts of neutral lipids. If this were the case, triglyceride-rich LDL in the plasma of transgenic animals might simply reflect the secretion of smaller lipoproteins by the liver.
A second puzzling feature of the human apo-B transgenic mice is their reduced plasma levels of HDL cholesterol. The reduction in HDL cholesterol levels was observed in male and female transgenic mice, both on a low-fat chow diet and on a high-fat diet (13). Reduced HDL cholesterol levels were also observed in the human apo-B transgenic rabbits (18). We suspect that reduced HDL cholesterol levels may be a hallmark of apo-B overexpression, although the metabolic basis for this finding has not yet been defined.
Generating Transgenic Mice Expressing
Mutant Forms of Apo-B
Even though the human apo-B cDNA and gene were cloned in the mid-1980s (19-21), progress in understanding human apo-B structure/function relationships has been slow. One reason for the slow progress is that introducing mutations into apo-B minigenes is difficult and timeconsuming.
Another reason is that cell culture systems for expressing human apo-B have typically provided insufficient amounts of apo-B for analysis.
After we demonstrated that transgenic mice could be used to express large amounts of human apo-B100, we sought to develop a system for expressing mutant forms of human apo-B in transgenic mice in order to examine apo-B structure/function issues. Many features of the apo-B molecule require further study, including the structure of the LDL receptor-binding domain, the role of the cysteinerich domain in the amino terminus of apo-B, lipid-binding domains, and the region of the apo-B100 molecule that interacts with apo(a) to form lipoprotein (a) [Lp(a)].
We decided to initiate our structure/function studies by addressing the structural features of apo-B100 that are required for Lp(a) assembly, beginning with the identification of the apo-B100 cysteine residue involved in the disulfide linkage with apo(a). Because prior studies had suggested that the critical cysteine was located within the carboxyl terminus of apo-B100 (8, 22, 23), we decided to test the hypothesis that the last cysteine in the apo-B100 molecule, cysteine-4326, was involved in the disulfide linkage. Testing this hypothesis required that we generate transgenic mice expressing a mutant human apo-B that lacked that residue. To introduce a mutation into a large genomic DNA fragment spanning the human apo-B gene, we decided to use gene targeting in a yeast artificial chromosome (YAC). We started by cloning the 80-kb insert from p158 into a YAC vector. After removing the URA3 gene from the YAC, we used "pop-in, pop-out" gene-targeting to change cysteine-4326 to a glycine ( Fig.5) (24) . Because of the extremely high efficiency of homologous recombination in yeast, modifying the apo-B-YAC by gene targeting was very easily accomplished. After the modification was completed, the YAC DNA was purified from a pulsed-field agarose gel and used to generate transgenic mice (24).
In in vitro assays, the mutant human apo-B (Cys4326Gly) lacked the capacity to bind covalently to apo(a) to form Lp(a) (Fig. 6) . Moreover, transgenic mice expressing both human apo(a) and the mutant human apo-B had no Lp(a) in their plasma (24, 25) . These studies showed that apo-B100 cysteine-4326 is required for the disulfide linkage of apo-B and apo(a) to form Lp(a) (24, 25) .
Since the initial studies with the Cys4326Gly mutation, the apo-B-YAC gene-targeting system has continued to work efficiently for mutating apo-B.
Subtle mutations can be introduced into the apo-B-YAC with 1 or 2 weeks of full-time effort, and the efficiency of generating transgenic mice with YAC DNA is equal to that obtained with P1 bacteriophage DNA. All of the necessary techniques for implementing this system, including the methods for preparing YAC DNA for microinjection, have been described in review papers (25, 26) . We expect that this YAC gene-targeting system will find widespread use in the analysis of other important structural features of the apo-B molecule, such as the region of apo-B100 that binds to the LDL receptor.
Transgenic
Mice for Understanding
Apo-B Gene Expression
Although the 80 kb insert from p158 allowed us to generate transgenic mice expressing high plasma levels of human apo-B, it is important to emphasize that the tissue pattern of transgene expression was not normal. The apo-B transgene was expressed at high levels in the liver, but intestinal expression was unexpectedly absent. Even extremely sensitive techniques, such as reverse transcriptase-polymerase chain reaction (RT-PCR), could not detect transgene expression in the intestine (13). The absence of intestinal transgene expression became overwhelmingly obvious when we mated the human apo-B transgenic mice (HuBTg+/0) with the apo-B knockout mice. The human apo-B transgenic mice that were homozygous for the knockout mutation (HuBTg+/0 apo-B-1-) developed normally, but they lacked all apo-B synthesis (mouse or human) in the intestine.
Because of their inability to synthesize and secrete chylomicrons, these mice had severe fat malabsorption and growth retardation (Fig. 7) . The absence of intestinal transgene expression from such a large fragment of genomic DNA was surprising because prior cell-culture studies had suggested that the sequences required for intestinal apo-B gene expression were contained within the proximal promoter of the apo-B gene (27, 28) .
We considered several possible explanations for the absence of transgene expression in the intestine. The first explanation (and the one that we considered most likely) was that the intestinal element was simply not present within p158. The second explanation was that the intestinal regulatory element was contained within the construct, but that this human regulatory element was not recognized by the mouse transcriptional machinery.
To test latter possibility, we generated mouse apo-B transgenic mice using an 87-kb genomic DNA fragment spanning the mouse apo-B gene. That fragment contained 33 kb of 5' flanking sequences and 11 kb of 3' flanking sequences (Fig. 8) . Two independent experimental approaches revealed that the mouse apo-B transgene was expressed at high levels in the liver but was not expressed in the intestine (29). First, RNase protection assays showed that the mouse apo-B transgene was expressed only in the liver, while the endogenous mouse apo-B gene was expressed in both the liver and intestine. (Distinguishing transgene expression from the expression of the endogenous gene was possible because the transgene contained a 2-bp apo-B gene polymorphism.) Second, we crossed the mouse apo-B transgenic mice (MusBTg+/0) with the apo-B knockout mice to generate transgenic mice that were homozygous for the knockout mutation (MusBTg+/0 apo-B-/-).
Like the HuBTg+/0 apo- The codon for cysteine-4326 was then changed to a glycine by site-directed mutagenesis.
A new Stul site was created in the process. The targeting vector was linearized at the EcoRl site in exon 29 of the apo-B gene and introduced into spheroplasts containing the 108-kb apo-B YAC. Transformants were initially selected on plates lacking uracil and later grown on plates lacking uracil, tryptophan, and lysine (44). To identify targeted clones after the "pop-in" step, yeast colonies were analyzed by pulsedfield gel electrophoresis (PFGE) and Southern blot analysis (24). For the "pop-out" step, yeast harboring a targeted YAC were grown overnight in medium lacking lysine and plated onto 5-fluoroorotic acid plates.
Colonies were subsequently analyzed by PFGE and Southern blot analysis.
The YAC DNA containing the Cys4326Gly mutation was then microinjected into mouse eggs to generate transgenic mice expressing the mutant form of human apo-B. B-/-mice (30), the MusBTg+/-apo-B-/-mice lacked the ability to synthesize chylomicrons and consequently had severe intestinal fat malabsorption and growth retardation (29). Generation of "Apo-B48-Only" and "Apo -B100-Only" Mice
All mammals synthesize two forms of apo-B : apo-B48 and apo-B100 (31, 32). Apo-B100 (4536 amino acids) is produced in the liver where it is an essential structural protein in the formation of VLDL. Apo-B48 (2152 amino acids) is produced in the intestine and plays an obligatory role in the assembly of chylomicrons.
Apo-B48 is synthesized by apo-B mRNA editing (33, 34) that changes codon 2153 (CAA, specifying glutamine) to a premature stop codon.
In some mammals, including mice and rats, apo-B mRNA is also edited in the liver ; consequently, the livers of these animals produce both apo-B48 and apo-B100 (33, 34).
Although apo-B48 and apo-B100 exist in all mammals, it is not clear why nature has gone to the trouble of making two different forms of apo-B.
It is not clear, for Fig. 6 . Western blot analysis of lipoprotein (a) formation. The ability of mutant apo-B100 to bind to apo(a) was assessed in the western blot assay described by Chiesa et al. (17) and modified by McCormick et al. (22) . The plasma from an apo(a) transgenic mouse (17) was used as a source of free apo(a).
Plasma from the apo(a) transgenic mouse was incubated with plasma from a wild-type human apo-B100 transgenic mouse, plasma from a human apo-B90 transgenic mouse (22), and plasma from a transgenic mouse expressing the mutant human apo-B100 (Cys4326Gly).
All incubation mixtures contained identical amounts of human apo-B, as judged by specific radioimmunoassays.
Aliquots of each of the incubation mixtures were resolved on 4% polyacrylamide-sodium dodecyl sulfate gels under nonreducing conditions and then transferred to nitrocellulose for western blots with the human apo(a)-specific monoclonal antibody, IgG-1A2. Lane 1 shows the plasma from the apo(a) transgenic mouse ; lane 2, the incubation mixture containing wild-type human apo-B100 ; lane 3, the incubation mixture containing human apo-B90 ; and lane 4, the incubation mixture containing the mutant human apo-B100 (Cys4326Gly). Reproduced, with permission, from McCormick et al. (24) . Callow and co-workers (45) have also generated transgenic mice lacking cysteine-4326 and have also concluded that cysteine-4326 is essential for the formation of lipoprotein (a). Photograph of 4-day-old suckling mice. The mouse on the right lacks apo-B synthesis in the intestine (genotype HuBTgapo-B-/-); the mouse on the left is a wild-type littermate control.
The HuBTgapo-B-/-mouse on the right is genetically incapable of synthesizing apolipoprotein (apo) B in the intestine and therefore cannot package alimentary fats into chylomicrons.
The inability to synthesize chylomicrons causes severe fat malabsorption and growth retardation and is associated with a massive accumulation of lipids in the enterocytes of the small and large intestines. The accumulation of lipids in the intestines causes the entire abdominal cavity to be white.
Modified, with permission, from Young et al. (30). example, why apo-B100 would not be perfectly suitable for the intestine.
Nor is it clear why apo-B48 alone would not suffice for both the liver and the intestine.
To approach this issue experimentally, we used gene-targeting to produce mice that synthesize exclusively apo-B48 (apo-B48-only mice) and mice that synthesize exclusively apo-B100 (apo-B100-only mice) (Fig. 9) (35) . To produce the apo-B48-only mice, we used "pop-in, pop-out" gene targeting in ES cells to introduce a TGA stop codon into codon 2153 of the mouse apo-B gene. To produce apo-B100-only mice, we introduced a "nonstop" mutation into codon 2153 by changing the CAA-glutamine codon to a CTA-leucine codon. When the CTA-leucine codon undergoes apo-B mRNA editing, a stop codon is not generated. As expected, mice that were homozygous for the apo-B48-only mutation (apo-B48/48) synthesized exclusively apo-B48, whereas mice that were homozygous the apo-B100-only mutation (apo-B100/100) synthesized exclusively apo-B100 (Fig. 10) .
We have examined the plasma lipids and lipoproteins of the apo-B48/48 and apo-B100/100 mice in detail (35). The apo-B48/48 mice had lower levels of LDL cholesterol than the apo-B100/100 mice (Fig. 11A ). Although the difference in LDL levels was relatively minor, this finding was unequivocal and was reproducibly present in repeated experiments over 18 months. In addition to lower LDL cholesterol levels, the apo-B48-only mice also had lower plasma triglyceride levels due to reduced levels of triglycerides in the VLDL and LDL fractions (Fig. 11B) .
We speculated that the lower LDL cholesterol levels in the apo-B48148 mice resulted from increased apo-Emediated clearance of the apo-B48-containing lipoproteins. To test this hypothesis, we crossed the apo-B48/48 and apo-B100/100 mice with apo-E-deficient mice (apo-E-/-) to generate apo-E-deficient apo-B48-only mice (apo-B48/48 apo-E-/-) and apo-E-deficient apo-B100 -only mice (apo-B100/100 apo-E-/-) (35). The apo -B48/48 apo-E-/-mice had higher cholesterol levels than apo = B+/+ apo=E-/-mice, whereas the apo -B100/100 apo-E-/-mice had lower cholesterol levels (Figs. 12A and B) . We strongly suspect that the lower levels of cholesterol in the apo-B100/100 apo-E-/-mice are due to the fact that the apo-B100-containing lipoproteins in these animals can be cleared by the LDL receptor.
The plasma triglyceride levels in the apo-B100/100 apo-E-/-and apo-B48/48 apo-E-/-mice were intriguing. Even though the apo-B48/48 apo-E-/-mice had increased plasma cholesterol levels, they had decreased triglyceride levels (Fig. 12B) , largely because of reduced VLDL triglycerides.
Moreover, the apo-B100/100 apo-E-/-mice had significantly higher levels of triglycerides, despite having lower levels of cholesterol (35). Thus, the apo-B100-only mutation had the effect of increasing triglyceride levels, whether or not the mice expressed apo-E. We have not yet investigated the metabolic basis for the relative hypertriglyceridemia in the apo-B100-only mice, but we are tempted to speculate that this finding might provide one clue for the existence of two forms of apo-B in mammalian metabolism.
It seems possible that apo-B48 exists as a protein that is specialized for the more rapid and complete unloading of triglycerides.
Because apo-B48 is present in the intestines of all mammals, we initially hypothesized that the intestinal synthesis of apo-B100 in the apo-B100-only mice might be suboptimal for the assembly of chylomicrons and for the promotion of fat absorption.
This did not appear to be the case. The intestinal histology of the apo-B100-only mice was normal ; there was no abnormal accumulation of cytosolic fat in the villus enterocytes on a chow diet, a high-fat diet, or after a bolus of corn oil. Electron microscopy (performed by Robert, Hamilton University of California, San Francisco) demonstrated large chylomicron particles in the enterocytes of the apo-B100-only mice. Retinyl palmitate absorption (a marker of chylomicron metabolism) was no different in the apo-B100-only and the apo-B48-only mice.
Although our studies have demonstrated that apo-B100 can assemble chylomicrons in the intestine and promote Apo-B Allele with Targeted  Mutation   apoB genotype fat absorption, we believe that it will be possible to document abnormalities of chylomicron metabolism in the apo-B100-only mice. In the studies of the apo-B100-only mice performed thus far, we suspect that the full complement of LDL receptors has interfered with our ability to detect an abnormality in chylomicron clearance. Ishibashi and Herz have performed studies suggesting that the LDL receptor-related protein (LRP) clears apo-B48-containing lipoproteins more efficiently than apo-B100-containing lipoproteins (36, 37) . They have also demonstrated that LRP-mediated clearance of lipoproteins can be directly assessed in mice that are deficient in LDL receptors.
We have hypothesized that the clearance of apo-B100 chylomicrons will be abnormal in apo-B100-only mice that are deficient in LDL receptors. In these mice, we suspect that the clearance of apo-B100-containing lipoproteins by the LRP pathway will be severely impaired. In apo-B48-only mice lacking LDL Fig. 9 . "Pop-in, pop-out" gene-targeting strategy for generating apo-B48-only and apo-B100-only mice.
Codon 2153 of the apo-B gene undergoes editing, changing a CAA (Glutamine) codon to a UAA stop codon.
The "pop-in, pop-out" sequence-insertion vectors contained a 10.5-kb fragment of the mouse apo-B gene, neo, and a tk in the plasmid backbone.
For the apo-B48-only vector, site-directed mutagenesis was used to change codon 2153 to a TGA stop codon.
To facilitate identification of targeted clones, the mutation was "tagged" with a unique Spel site. For the apo-B100-only vector, codon 2153 was changed to a CTA (leucine) codon, which, when edited, does not form a stop codon. This mutation was tagged with a Hindlll site. Targeting vectors were linearized at a unique Saul site within the apo-B gene and electroporated into embryonic stem (ES) cells.
To identify targeted cells (the "pop-in" step), genomic DNA from G418-resistant ES-cell clones was digested with Spel and Hindlll (for the apo-B48-only vector) or Hindlll (for the apo-B100-only vector) and analyzed by Southern blots with an apo-B gene probe from intron 25 to exon 25. Targeted apo-B48-only clones and targeted apo-Bl0-only clones were identified by novel 3.6-kb Hindlll-Spel and 3.6-kb Hindlll fragments, respectively.
The targeting frequency was Testing these hypotheses must await the development of LDL receptor-deficient apo-B48-only mice and LDL receptor-deficient apo-B100-only mice.
APOBEC-1 Knockout Mice
In 1987, Powell and co-workers demonstrated that apo-B48 is produced by specific mRNA editing that converts codon 2153 (CAA) to a premature stop codon (UAA) (38). Six years later, Teng and co-workers used an expression cloning strategy to identify the cDNA for the protein responsible for the apo-B mRNA editing (apo-B, mRNA editing catalytic peptide #1, or APOBEC-1) (39). Since those seminal studies, it has been obvious that it might be possible to generate "apo-B100-only" mice by knocking out the gene for APOBEC-1. In collaboration with A.
B.
Powell-Braxton Davidson, and Farese and co-workers, we have generated mice deficient in APOBEC-1 (40). Heterozygous mice had reduced levels of apo-B mRNA editing in the liver : however, the extent of apo-B mRNA= editing was normal in the intestine, suggesting that apo-B mRNA editing is present in excess in that tissue. Homozygous APOBEC-1 knockout mice had no apo-B mRNA editing activity in either tissue ; the plasma lipoproteins of those animals contained apo-B100 and absolutely no apo-B48 (40). The lipoprotein phenotype of the APOBEC-1= deficient animals appears to be identical to the apo-B100-only mice that we characterized earlier. We have recently performed a side-by-side comparison of apo-B100 levels and lipoprotein cholesterol distributions in the apo-B100/100 and the APOBEC-1-/-mice and have identified no differences.
The APOBEC-1 knockout mice develop normally and are healthy and fertile. This finding suggests that APOBEC-1 may not have a crucial role in the editing of transcripts from other genes.
Of course, our studies do not exclude the possibility that other mRNAs are edited by APOBEC-1 ; however, if other transcripts are edited, it would appear that the phenotypic consequences of this editing are subtle and do not perceptibly affect embryonic development, fertility, or the overall vitality of the animal.
Summary
Over the past 5 years, we have used a variety of transgenic and gene-targeted mice to study apo-B. Our studies have 1) helped to delineate a role for apo-B expression in mouse embryonic development (9, 15) ; 2) generated a new atherosclerosis-susceptible mouse that is suitable for investigating the genetic and environmental factors affecting atherogenesis (13) ; 3) led to a new understanding of the regulation of apo-B gene expression in the intestine (13, 26, 29, 41) ; 4) provided a system for investigating apo-B structure/function relationships (24, 25) ; and 5) yielded fresh insights into the "physiologic rationale" for the existence of two different forms of apo-B, apo-B48 and apo-B100, in mammalian metabolism (35). We see many opportunities for the continued use of genetically modified mice in apo-B research.
For example, the generation of additional transgenic animals will be critical for defining the DNA sequences that control intestinal expression of the apo-B gene and for defining the apo-B100 amino acid residues that interact with the LDL receptor. In addition, we anticipate that the generation of additional gene-targeted mice will lead to a more complete understanding of the human apo-B deficiency syndromes, hypobetalipoproteinemia and abetalipoproteinemia.
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(A) Distribution of cholesterol in the plasma lipoproteins. The plasma was fractionated by Superose 6 chromatography, as previously described (9, 
